Merck's Phase 3 trial for microsatellite-stable metastatic colorectal cancer treatment failed to improve overall survival.

Merck & Co. announced that its Phase 3 trial of the favezelimab and pembrolizumab combination for treating microsatellite-stable metastatic colorectal cancer did not meet the primary endpoint of improving overall survival compared to standard care. While the safety profile remained consistent with earlier studies, this setback follows other disappointing results for Keytruda in recent trials. Despite this, analysts maintain a positive outlook on Merck's stock.

September 25, 2024
11 Articles

Further Reading